CDKN2AIPNLP1

Across TCGA pan-cancer cohorts, CDKN2AIPNLP1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CDKN2AIPNLP1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where CDKN2AIPNLP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CDKN2AIPNLP1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

COAD, THCA, and KIRC are the cancer types where CDKN2AIPNLP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDKN2AIPNLP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	II,III,IV	+0.206	<.001	9	view →
THCA	All	II,III,IV	−0.068	.023	3	view →
KIRC	Male	II,III,IV	+0.061	.036	2	view →
LUSC	All	All	+0.045	.012	2	view →
BRCA	Female	II,III,IV	+0.039	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CDKN2AIPNLP1–COAD

Open the COAD breakdown →